Overview
- A federal jury in California found Apple infringed Masimo’s blood‑oxygen patent and awarded $634 million in damages.
- The verdict centers on U.S. patent 10,433,776, which expired in 2022, and cited Apple Watch workout mode and high‑heart‑rate notifications.
- Trial coverage said the damages calculation covered roughly 43 million Apple Watch units sold with the disputed feature.
- The ITC has instituted a combined modification and enforcement proceeding to assess whether Apple’s August 2025 iPhone‑processed Blood Oxygen redesign falls under its earlier exclusion order, targeting a decision within six months.
- U.S. Customs previously cleared imports of the redesigned models, a decision Masimo is challenging in court, while Apple is appealing the original ITC ban.